Kennedy staffer tapped for FDA leadership

One of Sen. Ted Kennedy's top committee aides will take a major role in the new FDA. David Dorsey, who's already been "detailed" to the FDA on behalf of Sen. Kennedy, will be developing agency policy and working with Congress in his new role, according to RPM Report. He'll also be a top counselor to acting FDA Commish Joshua Sharfstein.

By virtue of his previous work in the agency's Office of the Chief Counsel, Dorsey has a wealth of nitty-gritty knowledge, both about the agency's workings and about the legislation that governs it. He played key roles in developing the PDUFA reauthorization in 2002 and the big drug-safety reforms in 2007's FDA Amendments Act. As a co-author of the risk management strategies instituted by FDAAA, he's intimately familiar with their requirements. Plus, he's been involved in the copycat biologics debate; he worked on Kennedy's compromise bill that included 12 years of market exclusivity for biologic drugs before bioequivalent competitors would be allowed onto the market.

Dorsey's current appointment doesn't necessarily mean that he won't be named FDA Chief Counsel as some had expected. But that job will probably lack a permanent appointee until a general counsel for HHS is named. In the meantime, career FDA attorney Michael Landa is expected to be made Acting FDA Chief Counsel, RPM reports.

- see the story at RPM

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.